Profile: Sunesis Pharmaceuticals Inc (SNSS.O)

SNSS.O on Consolidated Issue listed on NASDAQ Capital Market

2.34USD
29 Jan 2015
Change (% chg)

-- (--)
Prev Close
$2.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,792,125
52-wk High
$8.45
52-wk Low
$1.00

Search Stocks

Sunesis Pharmaceuticals, Inc., incorporated on February 10, 1998, is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The Company focuses on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anti-cancer quinolone derivative (AQD). Vosaroxin has been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company licensed development and commercialization rights to vosaroxin from Dainippon Sumitomo Pharma Co., Ltd.

In January 2014, the Company announced the expansion of its oncology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec MA, Inc., is for global commercial rights to SNS-062, a potent and selective non-covalently binding oral inhibitor of Bruton’s tyrosine kinase (BTK). BTK is a mediator of B-cell receptor signaling that is integral to the pathogenesis of B-cell malignancies. With preclinical characteristics and activity distinct from compounds in the same class, SNS-062 may hold potential as a differentiated treatment for B-cell malignancies and other blood cancers. The second agreement, with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, is for global commercial rights to several potential first-in-class, pre-clinical inhibitors of the novel target phosphoinositide-dependent kinase-1, (PDK1). PDK1 is a key kinase and mediator of PI3K/AKT signaling, a pathway involved in cell growth, proliferation, differentiation, motility and survival.

The Company does not have internal manufacturing capabilities for the production of clinical or commercial quantities of vosaroxin. The Company relies on a limited number of third-party contract manufacturers for the production of clinical and commercial quantities of the vosaroxin active pharmaceutical ingredient, (API) and the finished drug product incorporating the API, (FDP).

Company Address

Sunesis Pharmaceuticals Inc

Suite 400
395 Oyster Point Boulevard
SOUTH SAN FRANCISCO   CA   94080
P: +1650.2663500
F: +1650.2663501

Company Web Links

Search Stocks